2. Disease Areas
  3. Infection
  4. Bacterial Infection

Bacterial Infection

Bacterial infections are caused by bacteria that typically arise from colonized sites in the patient, often following breach of local defense mechanisms, especially at mucosal injury sites, presenting with fever, flu-like symptoms, and localized inflammation; diagnosis relies on cultures and imaging. Pulmonary non-tuberculous mycobacterial (NTM) infection is a rare bacterial condition caused by environmental mycobacteria such as Mycobacterium avium complex, Mycobacterium kansasii, or Mycobacterium xenopi, leading to chronic respiratory symptoms including persistent cough, chest pain, hemoptysis, dyspnea, fatigue, fever, night sweats, and weight loss; risk factors include preexisting lung disease, malignancy, immunosuppression, or structural thoracic abnormalities, with individuals having compromised immunity or underlying health conditions being more susceptible due to exposure to mycobacteria in soil and water.

 

Bacterial Infection (32):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-D1056
    Lipopolysaccharides, from E. coli O55:B5
    Lipopolysaccharides, from E. coli O55:B5 (LPS, from Escherichia coli (O55:B5)) are endotoxins and TLR4 activators extracted from Escherichia coli (E. coli O55:B5) and are classified as S (smooth) type LPS. Lipopolysaccharides, from E. coli O55:B5 possess the typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from E. coli O55:B5 activate TLR-4 in immune cells, exhibit high pyrogenicity, and demonstrate dose and serotype specificity. Lipopolysaccharides, from E. coli O55:B5 can be widely used to induce cellular inflammation and establish animal models related to inflammation.
    It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.
    Lipopolysaccharides, from E. coli O55:B5
  • HY-D1056A1
    Lipopolysaccharides, from E. coli O111:B4
    Lipopolysaccharides, from E. coli O111:B4 (LPS, from Escherichia coli (O111:B4)) are endotoxins and TLR4 activators extracted from Escherichia coli (E. coli O111:B4) and are classified as S (smooth) type LPS. Lipopolysaccharides (LPS), from E. coli O111:B4 possess the typical three-part structure: O-antigen, R3-type core oligosaccharide, and lipid A. Lipopolysaccharides (LPS), from E. coli O111:B4 activate TLR-4 in immune cells and can cause significant gastric diseases. Lipopolysaccharides (LPS), from E. coli O111:B4 can be used to induce cellular inflammation and establish animal models related to inflammation.
    It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.
    Lipopolysaccharides, from E. coli O111:B4
  • HY-B0322S
    Sulfamethoxazole-d4 1020719-86-1 98.22%
    Sulfamethoxazole-d4 (Ro 4-2130-d4) is a deuterium labeled Sulfamethoxazole (HY-B0322). Sulfamethoxazole (Ro 4-2130) is a sulfonamide antibiotic with a widespread antibacterial activity. Sulfamethoxazole inhibits bacterial folate metabolism by competing with 4-Aminobenzoic acid (HY-B1008) (PABA) to act on dihydropteroate synthetase and dihydropteroate reductase. Sulfamethoxazole can be used for the study of urinary tract infections (UTIs), prostatitis, and bronchitis.
    Sulfamethoxazole-d<sub>4</sub>
  • HY-155048
    BDM91270 2892824-11-0 98.30%
    BDM91270 (compound 29) is an E. coli AcrAB-TolC efflux pump inhibitor with an EC90 of 0.6 μM for wild-type E. coli AcrB. BDM91270 can be used in the study of Escherichia coli drug resistance.
    BDM91270
  • HY-P99649
    Gremubamab 1800381-36-5
    Gremubamab (MEDI3902) is a humanized IgG1 kappa anti-PcrV/Psl monoclonal antibody. Gremubamab binds to the PA PcrV protein and Psl exopolysaccharide. Gremubamab has the potential for the research of pseudomonas aeruginosa infections.
    Gremubamab
  • HY-105373
    PNU 101850 852336-59-5
    PNU 101850 is an Eperezolid (HY-10393) ester prodrug. PNU 101850 acquires antibacterial activity after conversion to the parent drug Eperezolid.
    PNU 101850
  • HY-105291
    CKD-711 445010-62-8
    CKD-711 is an orally active aminooligosaccharide α-glucosidase inhibitor with an IC50 of 78 μg/mL. CKD-711 also inhibits porcine intestinal maltase and sucrose with IC50 values of 2.5 and 0.5 μg/mL. CKD-711 shows selective antibacterial activity against Comamonas terrigena. CKD-711 can be used for the researches of infection and metabolic disease, such as diabetes.
    CKD-711
  • HY-10391
    E-3709 128311-86-4
    E3709 is an antibacterial agent. E3709 exhibits significant inhibitory activity against Gram-positive bacteria, including Staphylococcus aureus (MRSA), Enterococcus faecalis, streptococci, Clostridia, and diphtheroids. E3709 can be used for research related to Gram-positive bacterial infections.
    E-3709
  • HY-D1056C3
    Lipopolysaccharides, from S. enterica serotype typhimurium
    Lipopolysaccharides, from S. enterica (Salmonella enterica) serotype typhimurium are lipopolysaccharide endotoxins and TLR4 activators derived from serotype typhimurium of Salmonella enterica, and are classified as S-type LPS. Lipopolysaccharides, from S. enterica exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from S. enterica serotype typhimurium can modulate the fate of bacteria in dendritic cells (DC), determining the uptake, degradation, and activation of immune functions by DC cells against the bacteria.
    It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.
    Lipopolysaccharides, from S. enterica serotype typhimurium
  • HY-B0502S
    Enrofloxacin-d5 1173021-92-5 99.82%
    Enrofloxacin-d5 is the deuterium labeled Enrofloxacin. Enrofloxacin (BAY Vp 2674) is an effective antibiotic with an MIC90 of 0.312 μg/mL for Mycoplasma bovis.
    Enrofloxacin-d<sub>5</sub>
  • HY-D1056D
    Lipopolysaccharides, from P. gingivalis
    Lipopolysaccharides, from P. gingivalis (LPS, from Porphyromonas gingivalis) are endotoxins and TLR4 activators extracted from Porphyromonas gingivalis (P. gingivalis) and are classified as S (smooth) type LPS. Lipopolysaccharides, from P. gingivalis possess the typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from P. gingivalis activate TLR-4 in immune cells and are important virulence factors in the mechanism of periodontal disease. Lipopolysaccharides, from P. gingivalis can be used in research related to periodontitis.
    It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.
    Lipopolysaccharides, from P. gingivalis
  • HY-17422S1
    Acyclovir-d4 1185179-33-2 98.66%
    Acyclovir-d4 is the deuterium labeled Acyclovir. Acyclovir (Aciclovir) is a guanosine analogue and an orally active antiviral agent. Acyclovir inhibits HSV-1 (IC50 of 0.85 μM), HSV-2 (IC50 of 0.86 μM) and varicella-zoster virus. Acyclovir can be phosphorylated by viral thymidine kinase (TK), and Acyclovir triphosphate interferes with viral DNA polymerization through competitive inhibition with guanosine triphosphate and obligatory chain termination. Acyclovir prevents bacterial infections during induction therapy for acute leukaemia.
    Acyclovir-d<sub>4</sub>
  • HY-P5753A
    JB-95 acetate 98.39%
    JB-95 acetate, a β-hairpin macrocyclic peptide, exhibits potent antimicrobial activity against Escherichia coli. JB-95 acetate can selectively disrupt the outer membrane but not the inner membrane of E. coli.
    JB-95 acetate
  • HY-D1056F
    Biotin-Lipopolysaccharide, from E.coli O111:B4
    Biotin-Lipopolysaccharide, from E.coli O111:B4 (Biotin-LPS, from Escherichia coli (O111:B4)) is a biotin-conjugated Lipopolysaccharide (LPS) (HY-D1056A1) that can be coupled with streptavidin protein. Biotin-Lipopolysaccharide, from E.coli O111:B4 can be used to identify Lipopolysaccharide ligands. Lipopolysaccharides, from E. coli O111:B4 (LPS, from Escherichia coli (O111:B4)) are endotoxins and TLR4 activators extracted from Escherichia coli (E. coli O111:B4) and are classified as S (smooth) type LPS. Lipopolysaccharides, from E. coli O111:B4 possess the typical three-part structure: O-antigen, R3-type core oligosaccharide, and lipid A. Lipopolysaccharides, from E. coli O111:B4 activate TLR-4 in immune cells and can cause significant gastric diseases. Lipopolysaccharides, from E. coli O111:B4 can also induce M1-type polarization in mouse macrophages.
    It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.
    Biotin-Lipopolysaccharide, from E.coli O111:B4
  • HY-P5710
    LCI peptide
    LCI peptide is an antimicrobial peptide with antibacterial activity. LCI peptide is active against plant pathogens, Xanthomonas and Pseudomonas, including E. coli, Gentamicin-resistant MRSA and Xoo.
    LCI peptide
  • HY-125733
    Thiocillin I 59979-01-0
    Thiocillin I is a thiopeptide antibiotic and has in vitro antibacterial activity against Gram-positive bacterial strains. The MIC values of Thiocillin I against S. aureus 1974149, E. faecalis 1674621, B. subtilis ATCC 6633 and S. pyogenes 1744264 are 2 μg/mL, 0.5 μg/mL, 4 μg/mL and 0.5 μg/mL, respectively.
    Thiocillin I
  • HY-19428A
    Ranbezolid hydrochloride 392659-39-1
    Ranbezolid (RBx7644 free base) is an orally active, oxazolidinone antibiotic against Gram-positive and Gram-negative anaerobes including Staphylococcus aureus, Staphylococcus epidermidis and Bacteroides fragilis. Ranbezolid can inhibit the 50s ribosomal subunit with an IC50 of 17 μM for bacterial ribosomes. Ranbezolid interferes cell wall and lipid synthesis. Ranbezolid can rapidly kill bacteria, significantly reduce bacterial load, and has better cardiovascular safety. Ranbezolid can be used for the study of antibiotics for anaerobic bacteria.
    Ranbezolid hydrochloride
  • HY-101702
    U-97456 129487-43-0
    U-97456 is a N-hydroxyacetyl derivate with antibacterial activity. U-97456 shows MIC <50 μg/mL against M. tuberculosis H37Rv. U-97456 can be used for the research of infection.
    U-97456
  • HY-105434
    CP-74667 108461-05-8
    CP-74667 is a quinolone antibacterial agent. CP-74667 shows high activity against Xanthomonas maltophilia (MIC50 = 1 μg/mL), Staphylococcus spp. (MIC50 = 0.06-0.12 μg/mL) and enterococci (MIC50 = 0.5-4 μg/mL).
    CP-74667
  • HY-E70064A
    Helicobacter pylori alpha-1,3-fucosyltransferase
    Helicobacter pylori alpha-1,3-fucosyltransferase (Hp3FT) catalyzes the glycosyl addition of fucose from the donor GDP-fucose to the acceptor N-acetyllactosamine.
    Helicobacter pylori alpha-1,3-fucosyltransferase